Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth

American Journal of Pathology

Volumn 169, Issue 5, 2006, Pages 1739-1752

  Gerber, Scott A ^a   Rybalko, Viktoriya Y ^a   Bigelow, Chad E ^a   Lugade, Amit A ^a   Foster, Thomas H ^a   Frelinger, John G ^a   Lord, Edith M ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; COLLAGEN TYPE 4; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HISTOLOGY; HYPOXIA; IMAGE ANALYSIS; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; OMENTUM; PERITONEUM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TUMOR GROWTH; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CELL HYPOXIA; CYTOLOGY; EPITHELIUM; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PERITONEAL CAVITY; PHENOTYPE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CELL HYPOXIA; CELL LINE, TUMOR; EPITHELIUM; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; NEOPLASM METASTASIS; OMENTUM; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PHENOTYPE; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36949008433     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051222     Document Type: Article

References (61)

1. Mahteme H, Hansson J, Berglund A, Pahlman L, Glimelius B, Nygren P, Graf W: Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004, 90:403-407
2. Healy JC, Reznek RH: The peritoneum, mesenteries and omenta: normal anatomy and pathological processes. Eur Radiol 1998, 8:886-900
3. Buy JN, Moss AA, Ghossain MA, Sciot C, Malbec L, Vadrot D, Paniel BJ, Decroix Y: Peritoneal implants from ovarian tumors: CT findings. Radiology 1988, 169:691-694
4. Sheth S, Horton KM, Garland MR, Fishman EK: Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003, 23:435-473
5. Lawrance RJ, Loizidou M, Cooper AJ, Alexander P, Taylor I: Importance of the omentum in the development of intra-abdominal metastases. Br J Surg 1991, 78:117-119
6. Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH: Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother 1998, 47:205-212
7. Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, Sakakura C, Tsujimoto H, Osaki K, Sasaki S: Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 1993, 53:687-692
8. Dullens HF, Rademakers LH, Doffemont M, Van Veen PT, Bulder R, Den Otter W: Involvement of the omental lymphoid organ in the induction of peritoneal immunity against tumor cells. Invasion Metastasis 1993, 13:267-276
9. Van Vugt E, Van Rijthoven EA, Kamperdijk EW, Beelen RH: Omental milky spots in the local immune response in the peritoneal cavity of rats. Anat Rec 1996, 244:235-245
10. Krist LF, Eestermans IL, Steenbergen JJ, Hoefsmit EC, Cuesta MA, Meyer S, Beelen RH: Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study. Anat Rec 1995, 241:163-174
11. Beelen RH: The greater omentum: physiology and immunological concepts. Neth J Surg 1991, 43:145-149
12. Ranvier L: Du development et de l'accroisement des vaisseux sanguins. Arch Physiol 1874, 1:429-450
13. Dux K, Rouse RV, Kyewski B: Composition of the lymphoid cell populations from omental milky spots during the immune response in C57BL/Ka mice. Eur J Immunol 1986, 16:1029-1032
14. Beelen RH, Fluitsma DM, Hoefsmit EC: The cellular composition of omentum milky spots and the ultrastructure of milky spot macrophages and reticulum cells. J Reticuloendothel Soc 1980, 28:585-599
15. Funda D, Holub M, Sykora V: Development of the cellular response in the mouse omentum after intraperitoneal immunization. APMIS 1993, 101:939-945
16. Ansel KM, Harris RB, Cyster JG: CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002, 16:67-76
17. Kirsch M, Schackert G, Black PM: Metastasis and angiogenesis. Cancer Treat Res 2004, 117:285-304
18. Wijffels JF, Hendrickx RJ, Steenbergen JJ, Eestermans IL, Beelen RH: Milky spots in the mouse omentum may play an important role in the origin of peritoneal macrophages. Res Immunol 1992, 143:401-409
19. Shimotsuma M, Shields JW, Simpson-Morgan MW, Sakuyama A, Shirasu M, Hagiwara A, Takahashi T: Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology 1993, 26:90-101
20. Koenen HJ, Smit MJ, Simmelink MM, Schuurman B, Beelen RH, Meijer S: Effect of intraperitoneal administration of granulocyte/macrophage-colony- stimulating factor in rats on omental milky-spot composition and tumoricidal activity in vivo and in vitro. Cancer Immunol Immunother 1996, 42:310-316
21. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424
22. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18
23. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039
24. Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 1996, 32A:2451-2460
25. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000, 92:143-147
26. Leenders WP, Kusters B, de Waal RM: Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9:83-87
27. Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM: Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer 2003, 88:1453-1461
28. Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM: Characterization of a lymph node within the mouse prostate: detailed analysis using whole mount histology. Prostate 2005, 63:105-116
29. Bigelow CE, Conover DL, Foster TH: Confocal fluorescence spectroscopy and anisotropy imaging system. Opt Lett 2003, 28:695-697
30. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM: Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 1998, 58:1478-1485
31. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
32. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248
33. Fonsatti E, Maio M: Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004, 2:18-24
34. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002, 277:43799-43808
35. Jerdan JA, Michels RG, Glaser BM: Extracellular matrix of newly forming vessels - an immunohistochemical study. Microvasc Res 1991, 42:255-265
36. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163:1801-1815
37. Egginton S, Zhou AL, Brown MD, Hudlicka O: Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res 2001, 49:634-646
38. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676
39. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177
40. Xiong M, Elson G, Legarda D, Leibovich SJ: Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 1998, 153:587-598
41. Ramanathan M, Giladi A, Leibovich SJ: Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Exp Biol Med (Maywood) 2003, 228:697-705
42. Cui L, Johkura K, Liang Y, Teng R, Ogiwara N, Okouchi Y, Asanuma K, Sasaki K: Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell Tissue Res 2002, 310:321-330
43. Gardner MJ, Jones LM, Catterall JB, Turner GA: Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995, 91:229-234
44. Bot J, Whitaker D, Vivian J, Lake R, Yao V, McCauley R: Culturing mouse peritoneal mesothelial cells. Pathol Res Pract 2003, 199:341-344
45. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE: Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002, 196:204-212
46. Lord EM, Harwell L, Koch CJ: Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993, 53:5721-5726
47. Koch CJ, Evans SM, Lord EM: Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995, 72:869-874
48. Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP: Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001, 27:359-363
49. Williams RHW: The greater omentum: its applicability to cancer surgery and cancer therapy. Curr Probl Surg 1986, 23:789-865
50. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186
51. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998
52. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK: Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997, 67:147-154
53. Pond CM: Paracrine interactions of mammalian adipose tissue. J Exp Zool Part A Comp Exp Biol 2003, 295:99-110
54. Mutsaers SE: The mesothelial cell. Int J Biochem Cell Biol 2004, 36:9-16
55. Visser CE, Tekstra J, Brouwer-Steenbergen JJ, Tuk CW, Boorsma DM, Sampat-Sardjoepersad SC, Meijer S, Krediet RT, Beelen RH: Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol 1998, 112:270-275
56. Kinnaert P, De Wilde JP, Bournonville B, Husson C, Salmon I: Direct activation of human peritoneal mesothelial cells by heat-killed microorganisms. Ann Surg 1996, 224:745-754
57. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB: Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol 2001, 281:L119-L125
58. Gary Lee YC, Melkerneker D, Thompson PJ, Light RW, Lane KB: Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002, 165:88-94
59. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP: CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 1999, 154:1525-1537
60. Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T: Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res 2004, 64:6065-6070
61. Tietze L, Borntraeger J, Klosterhalfen B, Amo-Takyi B, Handt S, Gunther K, Merkelbach-Bruse S: Expression and function of beta(1) and beta(3) integrins of human mesothelial cells in vitro. Exp Mol Pathol 1999, 66:131-139